High-speed Ultrahigh Resolution Optical Coherence Tomography before and after Ranibizumab for Age-related Macular Degeneration

Ophthalmology

Volumn 116, Issue 5, 2009, Pages 956-963

  Witkin, Andre J ^a   Vuong, Laurel N ^a   Srinivasan, Vivek J ^b   Gorczynska, Iwona ^a,b   Reichel, Elias ^a   Baumal, Caroline R ^a   Rogers, Adam H ^a   Schuman, Joel S ^c   Fujimoto, James G ^b   Duker, Jay S ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

ADULT; AGED; AQUEOUS HUMOR; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER PROGRAM; DIODE LASER; EYE INJURY; FEMALE; FOURIER ANALYSIS; HIGH SPEED ULTRAHIGH RESOLUTION OPTICAL COHERENCE TOMOGRAPHY; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; IN VIVO STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PHOTORECEPTOR; PIGMENT EPITHELIUM; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SIGNAL DETECTION; SPECTROSCOPY; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME; VASCULAR LESION; VOLUMETRY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; RETINA; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY; VITREOUS BODY;

EID: 65349095584     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2008.12.018     Document Type: Article

References (20)

1. Andreoli C.M., and Miller J.W. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 18 (2007) 502-508
2. Brown D.M., and Regillo C.D. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 144 (2007) 627-637
3. Brown D.M., Kaiser P.K., Michels M., et al., ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1432-1444
4. Rosenfeld P.J., Brown D.M., Heier J.S., et al., MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1419-1431
5. Kaiser P.K., Blodi B.A., Shapiro H., et al., MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114 (2007) 1868-1875
6. Stewart M.W. Predicted biologic activity of intravitreal bevacizumab. Retina 27 (2007) 1196-1200
7. Fung A.E., Lalwani G.A., Rosenfeld P.J., et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143 (2007) 566-583
8. Regillo C.D., Brown D.M., Abraham P., et al., PIER Study Group. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145 (2008) 239-248
9. Hee M.R., Baumal C.R., Puliafito C.A., et al. Optical coherence tomography of age-related macular degeneration and choroidal neovascularization. Ophthalmology 103 (1996) 1260-1270
10. Drexler W., Morgner U., Ghanta R.K., et al. Ultrahigh-resolution ophthalmic optical coherence tomography. Nat Med 7 (2001) 502-507
11. Srinivasan V.J., Wojtkowski M., Witkin A.J., et al. High-definition and 3-dimensional imaging of macular pathologies with high-speed ultrahigh-resolution optical coherence tomography. Ophthalmology 113 (2006) 2054-2065
12. Wojtkowski M., Srinivasan V., Fujimoto J.G., et al. Three-dimensional retinal imaging with high-speed ultrahigh-resolution optical coherence tomography. Ophthalmology 112 (2005) 1734-1746
13. Huang D., Swanson E.A., Lin C.P., et al. Optical coherence tomography. Science 254 (1991) 1178-1181
14. Leitgeb R., Hitzenberger C.K., and Fercher A. Performance of Fourier domain vs.time domain optical coherence tomography. Opt Express [serial online] 11 (2003) 889-894. http://www.opticsinfobase.org/abstract.cfm?URI=oe-11-8-889 Available at: http://www.opticsinfobase.org/abstract.cfm?URI=oe-11-8-889. Accessed September 15, 2008
15. Yun S., Tearney G., Bouma B., et al. High-speed spectral-domain optical coherence tomography at 1.3 μm wavelength. Opt Express [serial online] 11 (2003) 3598-3604. http://www.opticsinfobase.org/abstract.cfm?URI=oe-11-26-3598 Available at: http://www.opticsinfobase.org/abstract.cfm?URI=oe-11-26-3598. Accessed September 15, 2008
16. Choma M., Sarunic M., Yang C., and Izatt J. Sensitivity advantage of swept source and Fourier domain optical coherence tomography. Opt Express [serial online] 11 (2003) 2183-2189. http://www.opticsinfobase.org/abstract.cfm?URI=oe-11-18-2183 Available at: http://www.opticsinfobase.org/abstract.cfm?URI=oe-11-18-2183. Accessed September 15, 2008
17. Pieroni C.G., Witkin A.J., Ko T.H., et al. Ultrahigh resolution optical coherence tomography in non-exudative age related macular degeneration. Br J Ophthalmol 90 (2006) 191-197
18. Hughes E.H., Khan J., Patel N., et al. In vivo demonstration of the anatomic differences between classic and occult choroidal neovascularization using optical coherence tomography. Am J Ophthalmol 139 (2005) 344-346
19. Coscas F., Coscas G., Souied E., et al. Optical coherence tomography identification of occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 144 (2007) 592-599
20. Lafaut B.A., Bartz-Schmidt K.U., Vanden Broecke C., et al. Clinicopathological correlation in exudative age related macular degeneration: histological differentiation between classic and occult choroidal neovascularisation. Br J Ophthalmol 84 (2000) 239-243